Syndax enters new $200M at-the-market equity facility with TD Cowen, replacing prior $75M program

Syndax Pharmaceuticals Inc

Prior $75M ATM facility terminated on March 26, 2023; gross proceeds of $25M raised before termination.
New $200M ATM agreement signed May 26, 2023; shares sold at market prices through TD Cowen as agent.
Compensation to TD Cowen up to 3.0% of gross sales price; indemnification provisions included.
Offering may be suspended by either party; termination upon full sale or agreement end.
Cooley LLP legal opinion on Placement Shares filed as Exhibit 5.1 to the 8-K.

item 1.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Syndax Pharmaceuticals Inc terminated Prior Sales Agreement with Cowen and Company, LLC (effective 2023-03-26).

Action: termination
Agreement: atm program
Counterparty: Cowen and Company, LLC
Effective: 2023-03-26

Exact text from the filing

On March 26, 2023, Syndax delivered written notice to TD Cowen to terminate the Prior Sales Agreement pursuant to Section 11(b) thereof.

View on SEC.gov

Browse all material agreements →

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-024544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.